STING Signaling Augmentation in Radiation Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cancer therapies, such as radiation therapy, often fail to effectively activate immune responses against tumor cells due to the lack of stimulation of innate immune pathways, and the mechanisms for recognizing DNA-damaged cells for anti-tumor immune clearance remain unclear.
Innovation Solution
Administering radiation therapy to cancer patients who express the CCL5 gene, combined with type I interferon, to enhance STING signaling and activate phagocytes for anti-tumor CTL activity, thereby improving immunogenicity and anti-tumor efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If radiation therapy is administered to treat cancer, then tumor cells are damaged, but immune responses against tumor cells are not effectively activated
Solution Approach 1:
The patent introduces STING signaling pathway as an intermediary mechanism between radiation therapy and immune response activation. By targeting the STING pathway with cyclic dinucleotides (CDNs) or STING agonists, the system mediates the conversion of radiation-induced DNA damage into immunogenic signals that activate phagocytes and promote anti-tumor CTL activity, thereby resolving the contradiction between tumor damage and immune activation
Solution Approach 2:
The patent changes the biochemical parameters of the tumor microenvironment by inducing specific gene expressions (such as CCL5) and activating signaling pathways (STING-IRF3-NF-κB) in response to radiation therapy. This parameter change transforms the tumor cells from immunologically invisible to immunologically visible, enabling effective immune recognition and response while maintaining the therapeutic effect of radiation
2Reliability
If CCL5 gene expression is detected to identify responsive patients, then treatment efficacy can be improved, but the complexity of patient selection increases
Solution Approach 1:
The patent utilizes the tumor cells' own gene expression profile (CCL5) as a self-indicating marker for treatment responsiveness. Instead of requiring complex external assessment systems, the tumor cells themselves provide the selection criterion through their endogenous CCL5 expression levels, which can be detected through relatively simple molecular assays, thereby reducing the complexity of patient selection while maintaining high treatment efficacy
Data Source
AI summary
Following DNA damage events, such as radiation therapy, cytosolic dsDNA species are generated that trigger intrinsic STimulator of Interferon Genes (STING) signaling and render cells competent for phagocytic activation contingent on the chemokine CCL5 (C-C Motif Ligand 5). Loss of STING signaling or inducible CCL5, rendered DNA-damaged cells incapable of APC stimulation following phagocytosis. STING signaling facilitated the generation of immunogenic endosomal vesicles comprising the autophagy related proteins RAB9 and LC3, and cytosolic DNA which triggered APC activation in trans, an event which also required extrinsic cGAS/STING-dependent signaling. Further, the combination of radiation treatment in the presence of type I IFN greatly reduced tumor growth while rescuing the ability to generate CTL activity. Reconstitution of STING signaling and/or the combination of radiation treatment in the presence of type I IFN could significantly augment cancer therapy.